For illustration, assume COPD has already been established: three months after a maintenance-inhaler change, a patient reports acute worsening of breathlessness and cough. The mistake is to let the label “COPD exacerbation” automatically generate an antibiotic. The more useful family-medicine question is whether this patient’s change from baseline makes bacterial involvement likely enough to treat—and whether the patient is safe to manage outside the hospital.
Name the flare, then compare it with baseline
A COPD exacerbation is a sustained worsening of respiratory symptoms beyond day-to-day variation, commonly involving increased breathlessness, cough, and/or sputum. It describes a clinical event; it does not identify its cause. Viral infection, environmental exposures, and bacterial infection can trigger symptoms, while pneumonia, heart failure, and pulmonary embolism can mimic or worsen a flare.
Start by asking what is different for this patient. Clarify usual breathlessness and activity tolerance, usual sputum amount and color, oxygen use, rescue-inhaler use, and recent exacerbations or hospitalizations. Review inhaler access and technique, recent antibiotic courses, and any prior sputum culture results. A recent maintenance-inhaler change may warrant checking adherence and delivery, but it does not by itself point to a bacterial infection.
Assess severity at the same time. New respiratory distress, confusion, rapidly worsening symptoms, or concern for pneumonia or another serious illness should shift the visit toward urgent evaluation rather than a routine outpatient antibiotic decision.
Use sputum change as a probability shift—not a culture result
The classic Anthonisen symptoms are increased dyspnea, increased sputum volume, and increased sputum purulence. They describe symptom changes and have informed antibiotic decisions, but they do not confirm bacterial infection. New purulence—often described as yellow or green sputum compared with the patient’s usual sputum—raises the possibility of bacterial involvement, but does not identify a pathogen or prove that antibiotics will help.
| Change from baseline | What it contributes | What it does not establish |
|---|---|---|
| More breathlessness or cough | Supports an acute respiratory change | That the cause is bacterial or even solely COPD |
| More sputum or thicker sputum | Helps characterize the flare and its trajectory | Bacterial infection by itself |
| New purulent sputum | Makes bacterial involvement more plausible and can support antibiotic treatment | A specific organism or certainty that an antibiotic is needed in every case |
| Prior positive sputum bacterial culture | Can guide treatment if the patient has another flare | That the current symptoms are necessarily due to the same organism |
Do not mistake a symptom threshold for a bacterial diagnosis. GOLD’s detailed 2026 antibiotic criteria include at least two of four symptoms—increased dyspnea, fever, increased sputum volume, and sputum purulence—with purulence among the two; a positive sputum culture during a prior exacerbation; or a need for mechanical ventilation. Its key-points summary more briefly lists purulent sputum, prior positive sputum culture, or mechanical ventilation. NICE instead emphasizes an individualized decision that considers symptom severity, particularly sputum changes, hospital-treatment needs, exacerbation and admission history, prior cultures, complication risk, and antimicrobial resistance. These are decision frameworks, not microbiology results or proof that bacteria caused the current flare.
Keep the antibiotic decision separate from the rest of the flare plan
The acute COPD plan has several branches. Bronchodilator treatment, systemic corticosteroids when appropriate, oxygen for hypoxemia, and antibiotics each address different problems. Starting one does not automatically require starting the others.
If the patient is clinically stable, has no new purulent sputum or relevant prior positive culture, and has no separate diagnosis that calls for an antibiotic, do not prescribe one reflexively. Explain that the flare is real, but antibiotics treat bacterial infection—not airway irritation or a viral trigger. Make sure the patient knows what change should prompt another call or visit.
If antibiotics are indicated and outpatient care is appropriate, select a regimen using local recommendations, previous culture results, allergies, kidney function, recent antibiotic exposure, interactions, and resistance risk. Prefer the narrowest suitable option and avoid unnecessarily long courses; current international COPD guidance recommends no more than five days for outpatient exacerbations. A need for mechanical ventilation is a reason for hospital-level care, not simply for an outpatient prescription.
Make reassessment part of the prescription decision
A sputum culture is not needed for every uncomplicated flare. It may help guide therapy when resistance is a concern or results could change treatment—for example, with frequent exacerbations, severe airflow obstruction, exacerbations requiring mechanical ventilation, prior resistant isolates, or failure to improve after empiric antibiotics. Use culture results alongside the patient’s clinical response rather than changing therapy automatically.
Whether an antibiotic is prescribed or not, agree on a follow-up plan. Rapid or significant worsening calls for prompt reassessment. If symptoms are not beginning to improve within about two to three days—or the patient becomes systemically very unwell—reconsider the diagnosis and disposition. Ask again about pneumonia, heart failure, pulmonary embolism, and other causes rather than assuming that persistent breathlessness means the antibiotic needs broadening.
Practical takeaways
- An exacerbation is worsening beyond the patient’s usual baseline; it is not proof of bacterial infection.
- New sputum purulence is an important clue, not a definitive bacterial test.
- Use prior cultures, illness severity, recent antibiotics, and the patient’s trajectory to individualize the decision.
- Keep antibiotics separate from the other treatment branches, and safety-net whether you prescribe or not.
